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Abstract
mTOR is a kinase protein meaning it phosphorylates target proteins affecting their
cell signaling properties1. The drug Rapamycin, analogs of Rapamycin, and cell
signaling proteins that interact with mTOR control the activities mediated by
mTOR1. mTOR is located in the cytoplasm at a convergent point of many
signaling pathways that regulate a multiplicity of cellular processes including
metabolism that precede cell enlargement (cell “growth”), cell proliferation (cell
division), and angiogenesis1,2. Cells with mTOR inappropriately activated can
proceed with cell enlargement and cell proliferation in the absence of normal cell
signaling2. Rapamycin and Rapamycin analogs can inhibit mTOR and prevent
cell enlargement that precedes cell proliferation3,4.
We wanted to know if there is a concentration of Rapamycin that will inhibit cell
enlargement and proliferation of normal human hematopoietic stem cells (HSC)
under conditions that will still permit enlargement and proliferation of human
U937 leukemia cells. We performed experiments where we treated HSC and
U937 cells with Rapamycin. We compared the results of these experiments to see
whether there is a dose response difference to Rapamycin between the two cell
types.
We found that cell size of both HSC and U937 leukemia cells was affected to
comparable levels by Rapamycin at low nanomolar concentrations. However,
Rapamycin appeared to have a startling differential effect on cell proliferation of
HSC as compared to U937 cells. HSC proliferated very slowly or not at all in the
presence of low nM concentrations of Rapamycin. U937 cells on the other hand
were able to proliferate more strongly even at very high concentrations of
Rapamycin. Rapamycin inhibited the rate of cell proliferation to some extent but
it did not prevent the U937 cells from completing cell division and increasing in
number.
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Introduction
The mammalian target of Rapamycin (mTOR) is a kinase protein that
regulates many essential processes1. Cells with mTOR inappropriately “turned
on” proceed with cell division often when they are not supposed to2. As Figure 1
and Table 1 show, mTOR has been linked with many cancers, including breast
cancer, colon cancer, prostate cancer, lymphoma, and melanoma2.

Figure 1. Cancers in which mTOR is abnormally activated.

© Novartis Pharmaceuticals Corporation
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Table 1. The table lists mutations in upstream proteins that may lead to inappropriate activation of
mTOR. Representative cancer types are listed.

© Novartis Pharmaceuticals Corporation
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mTOR is a protein kinase located in the cytosol at a converging point of
numerous signaling pathways1,2. mTOR integrates the various signals and
determines the appropriate cell response1,2.
Since mTOR is a converging point of many signaling pathways, inhibiting
mTOR may affect crucial cell processes such as cell proliferation, angiogenesis,
or cell metabolism2. Abnormal expression of mTOR can lead to abnormal
regulation of these crucial processes2. Inhibition of abnormal mTOR expression
may provide an approach to cancer therapy. Inhibition of mTOR may enhance the
effect of other therapeutic agents or methods, and indeed, Rapamycin and analogs
of Rapamycin have been examined for anti-neoplastic efficacy3,4. In our
laboratory on the other hand, we are proposing to exploit the over-expression of
mTOR in leukemia cells as a novel approach to leukemia therapy rather than to
inhibit mTOR activity.
mTOR controls cell proliferation (cell division) by regulating the
production of cyclin D12. Cyclin D1 is involved in the regulation of cell passage
through the G1-S cell-cycle checkpoint2. This regulation is performed via the
activation of cyclin-dependent kinases 4 and 6 by cyclin D12. Many cancers show
overexpression of cyclin D12.
Angiogenesis, an essential process that provides nascent tumor cells with a
blood supply, requires the production of many factors such as vascular endothelial
growth factor (VEGF)2. mTOR controls the production of HIF1-α, also known as
hypoxia-inducible factor2. It is the HIF1-α which activates the angiogenesis
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factors2,5. In many cancers, HIF1-α is present at abnormal levels2. This can be due
to overproduction or failure to degrade HIF1-α factors2.
mTOR also regulates cell metabolism1,2,5. When nutrient levels are high,
mTOR activates protein synthesis1,2,5. Likewise, when nutrient levels are low,
mTOR inactivation leads to down regulation of protein synthesis and cell growth
arrest1,2,5. Many cancers grow inappropriately due to having mTOR “switched on”
upregulating protein synthesis2.
Our laboratory is particularly interested in exploiting inherent or
chemotherapeutically-induced differences in cell size between normal cells and
cancer cells as a possible approach to the physical destruction of enlarged cells.
Rapamycin and analogs of Rapamycin can control cell size by inhibiting cell
growth by specifically inhibiting mTOR2,5. Thus Rapamycin and Rapamycin
analogs are antagonistic to cytoskeletal-directed anticancer chemotherapeutic
agents such as Vincristine, Taxol, and Cytochalasin B that can cause cancer cells
to become greatly enlarged. Cancer cells with abnormal expression of mTOR
could become significantly enlarged under conditions where normal cells remain
small because their mTOR expression is correct. Thus, a combination of
cytoskeletal abnormalities along with errors in mTOR signaling may amplify the
size differences between normal and cancer cells.
We wanted to see if there is a dose-response effect of Rapamycin on cell
size and proliferation of human stem cells (HSC) in culture and U937 leukemia
cells in culture. We would like to know the conditions under which Rapamycin
inhibits cell enlargement and proliferation of HSC more strongly than it does of
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U937 leukemia cells. Moreover, we would like to know whether any
concentration dependent effects are present.
We performed experiments where we treated HSC and U937 cells with
Rapamycin. We found that HSC and U937 cells are affected in terms of cell
enlargement, although there may be a slight dose response difference between the
two cell types. However, Rapamycin appears to have a startling effect on cell
proliferation. As expected, HSC fail to proliferate in the presence of Rapamycin.
U937 cells, on the other hand, proliferate strongly in the presence of Rapamycin.
This differential characteristic may be further examined for sensitivity to physical
destruction and/or interaction with cytoskeletal-directed chemotherapeutic agents.

Literature overview
The focus of this literature overview is on the mTOR protein kinase and
its effects on cell size and the metabolic cycle. I will not elaborate on
angiogenesis or cell proliferation more than I have already. For definitions of the
various molecules mentioned please refer to Appendix A.

Discovery

In the 1970s, the bacterial strain Streptomyces hygroscopicus was shown
to produce a strong antifungal metabolite5. S. hygroscopicus is native to Easter
Island5. This macrocyclic lactone metabolite was named Rapamycin after the
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place of its discovery1,5. In the local language Easter Island is known as Rapa
Nui5.

Figure 2. Structure of Rapamycin showing the FKBP12-binding region and the mTOR-binding
region.

Rapamycin (Figure 2) suppresses immune response and cell proliferation6.
Through gene knockout mutations the target of Rapamycin (mTOR) was
identified in yeast5. Mutations mTOR1-1 and mTOR2-1 allowed the yeast
Saccharomyces cerevisiae to be resistant to Rapamycin5. It was also shown that
peptidyl-prolyl cis/trans isomerase FKBP12 is an essential intracellular co-factor
for Rapamycin effectiveness5,6. Rapamycin forms a complex with FKBP12 that
together binds and inhibits mTOR5.
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Structure
mTOR is highly conserved across eukaryotic species5. Every eukaryote
genome examined so far: yeast, algae, plants, flies and mammals among many, all
contain the mTOR gene5. Yeast have been found to contain 2 mTOR genes5.
Higher organisms contain only 1 gene5.
mTOR is a large protein (about 280 kDa)5,6. About 40%–60% of the
mTOR primary sequence is identical to the phosphatidylinositol kinase-related
kinase (PIKK) family of proteins5. At the carboxy-terminus end of mTOR the
PIKK family have a serine/threonine protein kinase domain5,6. This domain shares
features of the catalytic domain of phosphatidylinositol 3-kinases (PI3Ks) and
PI4Ks5,6.
The amino-terminus of mTOR contains the FKBP12-Rapamycin binding
domain (FRB) which is the binding site of Rapamycin (Figure 3)5. Mutations in
this domain yield mTOR proteins that no longer respond to inhibition by
FKBP12-Rapamycin complex5. Other selective mutations have uncovered many
domains of protein-protein interaction such as the C-terminal FAT and FATC
domains that are found in all PIKKs5. Another indication of protein-protein
interaction is the presence of HEAT sequences found at the amino terminus of
mTOR5. These HEAT sequences may extend and form helices offering regions
for protein-protein interaction5.
mTOR forms two distinct complexes (Figure 4)5,7. mTOR complex 1
(mTORC1) is sensitive to Rapamycin1,5. This complex dictates how the cell
grows1,5. mTOR complex 2 (mTORC2) is Rapamycin insensitive1,5. It dictates the
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actin cytoskeleton organization1,5. As such it controls cell motility, morphology,
position, polarization and location. mTORC2 is poorly understood5. The
complexes are distinct in the associated proteins they bind5,7. Both are multimers,
likely dimers5,7.

Figure 3. The binding of FKBP12-Rapamycin complex to the FRB domain of mTOR.
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Figure 4. The structure of the two distinct mTOR complexes and their respective functions.

Wullschleger, S., Loewith, R., Hall, M.N. (2006). TOR Signaling in Growth and Metabolism. Cell
124. 471-484.

Early Development

Experiments which involve the deletions of the mTOR gene in
Caenorhabditis elegans or in Drosophila melanogaster result in embryos that
show developmental arrests similar to starved larvae5. This indicates that mTOR
is important in the early stages of development where cell growth and
proliferation are of utmost importance5. For example, Bateman and McNeill have
shown that overexpression of mTOR in Drosophila accelerates differentiation5.
Likewise, underexpression of mTOR in Drosophila leads to slower
differentiation5.
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Experiments performed on mice also indicate the essentiality of mTOR
function5. Mouse embryos with missing mTOR show developmental problems
and often fail to survive because the defective embryos suffer from amino acid
deprivation5. When mouse cells are treated with Rapamycin, they also fail to
proliferate5.

Cell growth

In order to maintain homeostasis cells need to respond to nutrients
appropriately. When nutrients are abundant cells usually respond by increasing
their metabolic rate5. When mTOR is activated, cells show very high rates of
nutrient transport, ribosome biogenesis, and protein synthesis1,5.
Conversely, when nutrients are lacking cells will downregulate metabolic
rates to better conserve energy5. Studies of Rapamycin treated yeast have shown
that when mTOR is inhibited, translation is downregulated; macroautophagy and
other stress-response systems are initiated1,5.
Moreover, studies in yeast have also shown that mTOR is not only
responsible for how much the cell grows, but also where it grows1,5. mTOR2, not
mTOR1, regulates the polarization of actin skeleton1,5,7. In yeast that reproduce by
budding, mTOR2 allows actin to polarize toward the bud causing protein
synthesis and sequestration to be localized in the bud5. This function of mTOR2 is
insensitive to the effects of Rapamycin5. The effect of mTOR2 on actin
organization is conserved across organisms5.

11
Cell Growth Regulation Upstream

Growth Factors

mTOR is important in regulation of cell growth because it integrates the
various signals that the cell experiences such as the presence or absence of growth
factors (GF), nutrients, energy or stress1,5. When growth factors are present,
mTOR will respond via the PI3K pathway5. For example, Figure 5 shows how
insulin (a GF) stimulates the pathway. Upon its binding to the receptor, the insulin
receptor substrate (IRS) is phosphorylated which in turn attracts PI3K5. PI3K-IRS
complex then converts phosphatidylinositol-4,5-phosphate (PIP2) into
phosphatidylinositol-3,4,5-phosphate (PIP3)5. Phosphatase and tensin homolog
(PTEN), the enzyme that acts as a tumor suppressor, may antagonize the
accumulation of PIP35.
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Figure 5. Upstream and downstream mTOR signaling pathways.

Wullschleger, S., Loewith, R., Hall, M.N. (2006). TOR Signaling in Growth and Metabolism. Cell
124. 471-484.

Subsequently, PIP3 will recruit PDK1 and Akt to the membrane and
activate them by phosphorylation5. mTOR recognizes the PI3K pathway through
the tuberous sclerosis proteins TSC1 and TSC25. TSC1 is a hamartin and TSC2 is
tuberin5. Both act as a heterodimers that antagonize mTOR5. When insulin is
present, activated Akt phosphorylates TSC2, thereby rendering it inactive and
unable to form the heterodimer1,5.
TSC2 is a GAP (GTP-ase activating protein) for the Rheb molecule, which
is a GTPase5. There is no consensus on whether Rheb directly binds to the mTOR
kinase domain; however, there is agreement that Rheb induces a conformational
change in mTORC1, leading to the activation of mTORC15
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Nutrients
mTOR1 is regulated by amino acids, particularly the amino acid leucine5.
When leucine is absent mTOR effectors S6K1 and 4E-BP1 are
dephosphorylated5. When leucine is re-added the dephosphorylation is reversed5.
One way this regulation might come about is through the interaction of
amino acids with the TSC1-TSC2 complex5.The presence of amino acids has been
suggested to either inhibit the TSC1-TSC2 complex or to stimulate the Rheb
molecule5. When TSC-1 is inactivated the cell does not respond properly to the
presence of amino acids5. Other studies suggest that amino acids affect the
interaction and binding of Rheb and mTOR5. More recent studies have implicated
another molecule, hVPS34, a class III PI3K that signals to mTOR independently
of the TSC-Rheb complex5. The mechanism is not clear5.

Energy
The cell gauges the levels of energy based on the levels of AMP-activated
protein kinase (AMPK)1. Cell growth requires a lot of energy to synthesize
proteins at a high rate. Low levels of energy are characterized by a high
AMP/ATP ratio that activates AMPK1,5. When activated, AMPK inhibits protein
synthesis and activates ATP synthesis1,5. AMPK directly phosphorylates TSC2,
enhancing its activity5. Experiments done using the AMPK analog called AICAR
have shown mTORC-1 inhibition of S6K1 and 4E-BP15.
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Stress
Cells respond to stress, such as hypoxia (low oxygen) by downregulating
processes that require a lot of energy, such as cell growth5. When a cell
experiences hypoxia it downregulates mTOR and protein synthesis is inhibited1.
Experiments performed on Drosophila and mammalian cells have shown that
cells recognize hypoxia through the REDD1 and REDD2 proteins5. When the cell
experience hypoxia, HIF1 stimulates the production of REDD molecules5. REDD
molecules act downstream of Akt but upstream of TSC5. REDD inhibits mTOR15.
Since hypoxia leads to eventual ATP depletion, it is suggested that the AMPK
pathway and REDD pathway are interrelated5. The mechanism is still unknown5.
Cells experience other stresses5. When p53 senses DNA damage it signals
to mTOR via the AMPK-TSC2 signaling pathway5. Other stresses include the
presence of reducing agents in the environment5. Reducing agents have been
suggested to inhibit mTOR via a redox sensor in the FAT domain of mTOR5.

Cell Growth Regulation Downstream

Ribosome Biogenesis
The creation of ribosomes is a very energy-consuming process5. It is
essential for a cell to have a ribosome control mechanism that responds to the
changes of cellular energy levels5. Studies have shown that mTOR controls the
synthesis of ribosomes by controlling the transcription of RNA polymerase Idependent rRNA genes, RNA Polymerase II dependent ribosomal protein genes,
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RNA Polymerase III dependent tRNA genes and also by controlling 35S rRNA5.
In humans and mice, mTOR controls ribosome synthesis by inhibiting these
genes5. mTOR has been shown to control transcription by forming complexes
with transcription initiation proteins, such as Pol I associated TIF1A5. Cells
treated with Rapamycin showed inactivation of TIF1A and prevention of
transcription5. FHL1 Pol II associated transcription factor has been shown to be
essential for regulation of Pol II-dependent RP gene expression5.

Transcription/Translation
Translation is regulated by S6K1 and 4E-BP, both of which are regulated
by mTOR5. mTOR activates S6K1 through phosphorylation at Thr3895. The
second phosphorylation comes from PDK15. It is unknown how S6K1 augments
translation5. mTOR 1 phosphorylation has been shown to be important in the
nuclear localization of several transcription factors5.

Actin
mTOR2 complex controls the polarization of actin molecules1,5. mTOR
signals to actin through Rho1 GTPase5. Rho1 then signals to PKC1 which in turn
activates the MAP kinase pathway that reorganizes the actin cytoskeleton5. How
TOR signals to Rho1 is not understood5
Rosner et al. show that the effects on cell cycle and cell size by mTORC1
and mTORC2 appear to be separate7. However, mTORC2 appears to not only

16
control actin reorganization but also regulates cell size and cell cycle via Akt,
TSC2 and Rheb cell signaling7. This is independent of mTORC1 signaling7.

Macroautophagy
Macroautophagy occurs when cells that are without nutrition for a
prolonged time begin to degrade cytoplasmic contents to maintain energy levels1.
ATG1 is a kinase that activates macroautophagy5. mTOR has been implicated in
yeast and higher organisms in controlling this process5. Yeast studies have shown
that TOR inactivates a protein kinase ATG15. When mTOR is inactivated,
macrophagy is initiated and the cells begin this catabolic process5.

Metabolism
Metabolic processes such as amino acid synthesis, glucose homeostasis
and fat metabolism are controlled by mTOR as well5. Rapamycin treatment
inhibits adipogenesis, which is poorly understood5. However, the mechanism
seems to involve mTOR and S6K1 since mTOR signals to S6K15. S6K1 mutants
inhibit fat accumulation5. Moreover, flies with inactivated mTOR show fat
deficiency5.
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Materials
Fetal Bovine Serum, Atlanta Biologicals, premium, triple 0.1 µm filtered.
StemSpan SFEM: Serum Medium for Expansion and Culture of Hematopoietic
Cells, Stem Cell Technologies.
Amphotericin B (Fungisone) 0.250 µg/ml, Sigma.
Penicillin-Streptomycin: 10,000 units penicillin and 10 mg streptomycin per ml in
0.9% NaCl, Sigma.
L-Glutamine: 200 mM, Sigma.
Gentamycin Sulfate: 10 mg/ml, BioWhittaker.
StemSpan Cytokine Cocktails, 100X (Flt-3, SCF, IL-3, IL-6) Stem Cell
Technologies.
Iscove’s Modified Dulbecco Medium with NaHCO3 and 25 nM Hepes. No
glutamine, thioglycerol, BME, BioWhittaker.
Rapamycin: Sigma.

Methods
Experiment 1
The U937 Cells: The R1A Line Day 8 plateau-phase cells were checked for
viability. They were sub-cultured to 5 x 10E4 Cells/ml in Iscove’s Modified
Dulbecco’s Medium with 20% FBS, 1% FGZ (Amphotericin B) (2.5 µg/ml), 1%
Gln (2 mM), 2% Pen-Strep (200 units penicillin, 200 µg streptomycin per ml),
0.5% Gentamycin (200 µg/ml) in 5% CO2 at 37oC. They were grown for 24
hours. Cells were counted before seeding and checked for viability. The cells
were seeded 500 µl into 1 ml wells in a 48-well plate. Rapamycin 40 µM in EtOH
was given to final concentrations of 800, 400, 200 (10 µl, 5µl, 2.5 µl). A 5 µM
Rapamycin Stock Solution in EtOH (10 µl, 5 µl, 2.5 µl) was used to give 100, 50,
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and 25 nM Rapamycin. Control wells were either untreated or treated with 1.9%
EtOH. Cells were Coulter counted at days 1 and 4, at every micron size from 8µm
to 22µm.

Human Stem Cells: Were revived on March 11, 2009, from cells that were stored
at the temperature of -86oC on November 17, 2006. They were grown for one
week in 20% FBS Iscove’s, 1% FGZ, 1% Gln, 1% Stem Span from Stem Cell
Technologies. Before seeding cells were counted with a hemocytometer and
checked for viability using trypan blue. The cells were seeded in a volume of 500
µl into 1 ml wells of 48-well plate. Rapamycin treatment was same as for U937
cells. The cells were Coulter counted at days 1, 4, 8, and 9. They were counted at
every micron size from 8µm to 18µm.

Experiment 2
U937 Cells: The R1A Line Day 6 late log-phase cells were checked for viability.
They were sub-cultured to 5 x 10E4 Cells/ml in 20% FBS Iscove’s, 1% FGZ, 1%
Gln. They were grown for 24 hours. Rapamycin solutions were prepared by
making 4 µM Rapamycin in 95% EtOH using 40 µM Rapamycin Solution. At the
day of treatment there were 1.3 X 10E5 Cells/ml in 4 ml flasks. There were 8
flasks total. Six flasks (40, 20, 10, 5, 2, 1 nM) were treated with 40, 20, 10, 5, 2,
and 1µl of 4 µM Rapamycin, respectively. Control cells were either untreated or
treated with 0.95% EtOH. Cells were Coulter counted at days 1 and 4, at every
micron size from 8µm to 22µm.
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Three days later Rapamycin was removed from flask. Rapamycin-free medium
was added (medium dilution is 1:100 after addition of 5 ml medium to 50 µl
residual medium and cells). Growth was monitored at 3, 6, 9, and 21 hours after
Rapamycin-removal.

Experiment 3
U937 Cells: R1A Line Day 4.5 log-phase cells were checked for viability. They
were diluted 1:4 to ~5.5 x 10E4 Cells/ml in 20% FBS Iscove’s, 1% Gln, 1% FGZ.
One ml of cells was inserted into the 1st well in 8 well series of 48 well plate.
Subsequent 7 wells received 0.5 ml of cells. Well 1 received 8 µl of 4 µM
Rapamycin in 95% EtOH. Serial transfer of 500 µl from 1st well through 7th well
gave 32, 16, 8, 4, 2, 1, 0.5 nM Rapamycin concentrations. The last well received
no transfer (untreated/control U937 cells). Second to last well (0.5 nM) had 1.0 ml
cells and not 500 µl. Cells were counted with Coulter Counter after 72 hours.

Stem Cells: Cells were freshly prepared by Dr. Prabal Banergee, Upstate Medical
School, June 26, 2009. They were grown in Stem Cell Expansion Medium + 1%
FGZ + 1% Gln + 5% FBS for four days and checked for viability. Cells were
diluted 1:10 with Stem Cell Expansion Medium + 5% FBS + 1% Gln, 1% FGZ to
~ 5 x 10E4 Viable Cells/ml. Three days later they were Rapamycin-treated in 7
wells as for U937 cells. Rapamycin treatment was the same as for U937 cells.
U937 and Stem Cells were counted with a Coulter Counter after 72 hours.
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Results/Discussion
Experiment 1

We wanted to determine the dose-response effect of Rapamycin on HSC and
U937 human leukemia cells over the Rapamycin range from 800 nM to 25 nM.
Table 2 lists the effect of Rapamycin treatment on cell size (average cell volume)
of HSC and U937 leukemia cells.

Table 2. The effect of 800 to 25 nM Rapamycin concentrations on cell size inhibition of U937
leukemia cells and HSC.

Rapamycin

U937 Avg.
Volume

Conc (nM)
0
800 (1.9% EtOH)
400 (0.98% EtoH)
200 (0.48% EtOH)
100 (1.9% EtOH)
50 (0.98% EtoH)
25 (0.48% EtOH)

8u & <
2083
1462
1458
N/A
1500
1536
1829

HSC Avg
Volume
%
inhibition
30
30
N/A
28
24
12

8u & <
900
872
715
645
682
619
698

%
inhibition
3.1
21
28
24
31
24

Figure 6a shows the effect of 800 nM and 400 nM Rapamycin on the size
distribution of early log U937 cells 2 days after Rapamycin treatment. 200 nM
results are not included due to an experimental error.
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Figure 6a. The effect of Rapamycin on average cell volume of U937 cells two days after
treatment. Red bars represent average volume of cells 13µm and higher. Blue bars represent the
average volume of cells 8µm and higher.

Average cell volume of the U937 cells decreased. When compared with control
cells, 800 and 400 nM Rapamycin concentrations decreased average cell volume
by 30%. The 100 nM concentration inhibited cell size by 28%. The 50 nM
Rapamycin inhibited cell size by 24%. The 25 nM Rapamycin concentration
inhibited cell size by 12%. EtOH treated cells showed slight size inhibition, about
6.5%.

Table 2 and Figure 6a both show the predicted response of human leukemia cells
to Rapamycin in terms of cell size. All bar graphs in Figure 6a show cell size
inhibition. At this point, it appeared that lower Rapamycin concentrations affected
cell size less than did the higher Rapamycin concentrations.
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We also checked the effect of Rapamycin on cell proliferation.
Figure 6b. Linear growth graph representing the effect of Rapamycin on cell proliferation of U937
leukemia cells.

As figure 6b shows, Rapamycin appears to have an effect on cell proliferation.
The data at this point show no concentration-dependent effect of Rapamycin on
cell proliferation since 800 nM and 100 nM cells were inhibited the most. This
may be due to the different concentrations of EtOH that were used to dissolve
Rapamycin. Proliferation was inhibited by about 50% to 75% but the cells still
continued to proliferate. U937 cells can “grow through” the Rapamycin cell
enlargement block.
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Figure 6c. Exponential curve graph showing the effect of Rapamycin on cell proliferation of U937
leukemia cells.

Figure 6c shows an exponential growth curve of the effect of Rapamycin on cell
proliferation of the U937 cells. Again, there is no evidence of a dose dependent
effect of Rapamycin on cell proliferation of U937 leukemia cells.

Next we wanted to see whether human stem cells show a similar trend, and we
wanted to establish the dose response of HSC to Rapamycin.
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Figure 6d. The effect of Rapamycin on the average volume of HSC two days after Rapamycin
Treatment. The blue bars represent the average volume of cells 8µm or higher.

Figure 6d shows that HSC treated with Rapamycin become smaller. EtOH control
cells had reduced cell volume by 8.5% as compared with non-EtOH control cells.
As table 2 lists, the 800 nM concentration inhibited cell size by 3.1%, 400 nM
concentration inhibited cell size by 21%, and 200 nM concentration inhibited cell
size by 28%. Rapamycin at 200 nM actually reduced cell volume more than the
400 nM or 800 nM dose. It appears that 800 nM did not affect cell volume at all.

The 100 nM Rapamycin concentration inhibited cell size by 24%. The 50 nM
concentration inhibited cell size by 31%. The 25 nM concentration inhibited cell
size by 22%. Rapamycin at 50 nM reduced HSC cell volume more than any of the
other Rapamycin concentrations did. There was no evidence of a dose dependent
response of HSC to Rapamycin concentrations.
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Figure 6e shows the effects of Rapamycin on cell proliferation.
Figure 6e. Effect of 800 nM to 25 nM Rapamycin on cell proliferation of HSC.

At day 2 of Rapamycin treatment, all Rapamycin concentrations permitted slight
cell proliferation. However, cell proliferation was markedly reduced by day 8 of
Rapamycin treatment. The cell number went down noticeably by day 8. This
could be due to cell death or cell differentiation. Rapamycin removal experiment
should be performed to establish toxicity of Rapamycin for both HSC and U937
cells.

From this experiment we concluded that 1.9% EtOH itself affects cell
proliferation and cell volume slightly for both U937 human leukemia cells and for
human stem cells. This may be important since we used EtOH as a Rapamycin
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solvent. Moreover, we used different concentrations of EtOH. Future experiment
should use Rapamycin dissolved in one constant concentration and the results
should be compared to these results.

Stem cells are generally much smaller in diameters and average cell volumes than
are U937 leukemia cells. Our experiment shows that this characteristic is
maintained despite Rapamycin treatment. Both types of cells had inhibited cell
size and lower cell volume when treated with Rapamycin. No apparent
differential dose-response to Rapamycin between the HSC and U937 cells was
observed. Rapamycin treated stem cells showed much lower cell proliferation, as
expected. U937 cells on the other hand continued to proliferate in the presence of
Rapamycin.

Stem cells showed an unusual response to very high doses of Rapamycin at 800
nM by failing to be inhibited in their loss of cell volume and by continuing to
proliferate slightly. Moreover, stem cells used here are only 52% trypan blue
viable, growing 8 days after freezer revival. Rapamycin effects should be
determined on freshly-derived stem cells never frozen, and in full viable
proliferation.
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Experiment 2
In this experiment we expanded on the previous experiment by lowering the
Rapamycin concentration used. We wanted to see the effect of a 3-day treatment
with Rapamycin on U937 leukemia cells over a concentration range from 40 nM
to 1nM. We looked at cell size, cell proliferation and trypan blue viability. Table
3 shows the effect of Rapamycin on average cell volume of U937 cells. We also
looked at the re-growth of leukemia cells after Rapamycin was removed.
Table 3. The effect of Rapamycin on average cell volume of U937 cells 2 days after treatment.

Rapamycin
Conc (nM)
0
40 (0.95% EtOH)
20 (0.5% EtOH)
10 (0.25% EtOH)
5 (0.12% EtOH)
2 (0.05% EtOH)
1 (0.025% EtOH)

U937 Avg. Volume
8u & <
2048
1579
1682
1720
1877
1723
2017

% inhibition
23
18
16
8.3
16
1.5

Figure 7a shows size-distribution of control cells, 0.95% EtOH treated cells and
40 nM Rapamycin treated cells at day 2.
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Figure 7a. Size-distribution of control cells, 0.95% EtOH treated cells and 40 nM Rapamycin
treated cells at day 2.

The controls varied slightly at 2 days. The mid-log phase cells (at the beginning
of Rapamycin treatment) got smaller in 2 days as they reached plateau-phase.
EtOH treated cells when compared to control cells at day 0 had cell size inhibition
of 15%. EtOH treated cells compared to day 2 control cells had 6.25% size
inhibition. Subsequent cell size inhibition calculations use the Day 2 plateauphase cells as control cells. The 40 nM Rapamycin treated U937 cells had 23%
cell size inhibition.

Figure 7b shows the effect of 40 (repeated from above), 20 and 10 nM Rapamycin
concentrations on U937 cells.
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Figure 7b. The effect of Rapamycin 40, 20 and 10 nM concentrations on the cell size of U937
cells.

20 nM Rapamycin concentration showed 18% cell size inhibition. The 10 nM
Rapamycin treatment showed 16% cell size inhibition.

Figure 7c shows Rapamycin concentration range of 10, 5, 2, and 1 nM at day 2 of
treatment.
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Figure 7c. The effect of Rapamycin concentration range of 10, 5, 2, and 1 nM at day two of
treatment on the average cell volume of U937 leukemia cells.

5 nM Rapamycin inhibited cell size by 8.3%. The 2 nM inhibited cell size by
16%, much more than the 5 nM dose. The 1 nM treatment inhibited cell size by
1.5%. It appears that somewhere between 1 nM to 5 nM Rapamycin begins to
allow for cell enlargement.

The 2 nM concentration result is difficult to interpret because it might be due to
experimental error. The 2 nM treatment should be repeated for both HSC and
U937 cells to see whether Rapamycin affects cell size of HSC more strongly than
of U937 cells. The 1 nM Rapamycin did not seem to affect the U937 cells.
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Figure 7d shows the effect of Rapamycin on cell proliferation of the U937
leukemia cells.

Figure 7d. The effect of 40 nM to 1 nM Rapamycin on cell proliferation of U937 cells two days
after treatment.

Cell proliferation was inhibited at 40 nM to 1nM Rapamycin concentrations.
Higher Rapamycin concentrations (40 nM) inhibited cell proliferation more
strongly than did lower Rapamycin concentrations (1 nM). However, Rapamycin
continued to permit cell proliferation. Rapamycin appears to not prevent U937
cells from proliferating.

After 3 days of treatment with 20 nM Rapamycin, removal of 99% of the
Rapamycin (50 µl remaining after centrifugation and removal of Rapamycin-
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medium, and suspension in 5 ml of medium) cells showed re-growth and increase
in average volume between 9 and 21 hours after Rapamycin removal. Rapamycin
appeared to have no toxicity on the treated cells.

We concluded that 0.95% EtOH affects cell proliferation and cell volume
significantly, and should be taken into consideration when performing other
experiments.

Rapamycin shrinks cell volume and inhibits proliferation at 40, 20, and 10 nM. It
continues to have an effect at 5 nM and 2 nM concentrations. However, the effect
of Rapamycin at concentrations 40 to 1 nM on cell size and proliferation is less
strong than the effect of Rapamycin at concentrations 800 to 25 nM.

U937 cells can increase in size and can proliferate in the presence of 1 nM
Rapamycin. It is important to determine the does-response limit of human stem
cells and compare it to the U937 cells.

In addition, Rapamycin can be removed from cells treated with 20 nM Rapamycin
and cells can begin to proliferate after 9 hours in Rapamycin-free medium
(residual Rapamycin = 0.2 nM).
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Experiment 3

In this experiment we compared the Rapamycin dose-response of HSC and U937
cells over the concentration range 32 nM to 0.5 nM. This time we used freshly
derived human stem cells that we obtained from Dr. Prabal Banerjee, Upstate
Medical School.

Stem cells used for Rapamycin treatment were Day 7 growth cells, 65% trypanblue viable. They were grown in a multi-well plate with Rapamycin for 3 days
from Day 7 to Day 10. In untreated control cells viability was 97% by day 10.

Table 4. The effect of Rapamycin on average cell volume and cell size inhibition of HSC and
U937 cells.

U937 Avg.
Volume
Conc
(nM)
0
32
16
8
4
2
1
0.5

8u & <
1800
1465
1384
1443
1504
1609
1723
1759

HSC Avg
Volume
% inhibition
19
23
20
16
11
4.8
2.3

8u & <
742
653
671
668
730
723
723
760

% inhibition
12
9.5
10
1.6
2.6
2.6
-0.24

Table 4 shows the percent inhibition of Rapamycin on HSC and U937 cells on
cell size. Both types of cells showed size inhibition; however, HSC cells were
more strongly inhibited than were the U937 cells. The 0.5 nM concentration of
Rapamycin had no effect on cell size.
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Figure 8a shows the differential effect of Rapamycin on U937 cells and HSC in a
graphical form.

Figure 8a. The effect of Rapamycin on cell proliferation and average cell volume of U937 cells
and HSC cells.

Rapamycin reduced cell volume for both U937 leukemia and HSC by about 10 to
20%. The differential dose response of U937 cells and HSC might exist in the
range of 0 nM to 4 nM Rapamycin concentration. The data are inconclusive at
this moment.

Cell proliferation on the other hand showed a startling result. Both figures 8a and
8b show cell growth and proliferation. As compared to a 10-fold increase of the
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untreated cells, U937 cells were able to proliferate in the presence of 8 to 1 nM
Rapamycin by 6- to 8 fold-.

Figure 8b. The effect of Rapamycin on cell proliferation and average cell volume of U937
leukemia cells and HSC

On the other hand, when compared to the 3-fold increase of untreated cells, HSC
did not proliferate at all at 8 nM, and proliferated weakly at 2nM and 4 nM
Rapamycin.

Leukemia cells were Rapamycin-treated in 20% FBS, whereas Stem Cells were
treated in SCEM to allow for stem cell proliferation. If U937 leukemia cells
proliferate in SCEM, Rapamycin treatment should be done in SCEM for both
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Stem Cells and U937 cells to make sure that Rapamycin is not being bound by
20% FBS, reducing its effect on leukemia cells.

Rapamycin treatment should be repeated at concentrations from 8 nM, serially
diluted to 4, 2, 1, 0.5, 0 25, 0.125 nM. Two sets of wells should be used for U937
and two for Stem Cells. Treatment should be in identical media allowing for
growth of both stem cells and U937 cells.

Conclusions
In these laboratory experiments we wanted to establish whether there are
conditions under which Rapamycin will affect HSC more strongly than U937
leukemia cells. We found that, in terms of cell enlargement, there may be a
differential dose-response to Rapamycin between human leukemia cells and
human stem cells to Rapamycin; however, the data are inconclusive and further
analysis is required. Ultimately, we would like to see if there is a concentration of
Rapamycin that will inhibit cell enlargement of normal cells while still permitting
enlargement of leukemia cells by amplifying the size differences between normal
and leukemia cells without additional treatments.

More startling is lack of effect of Rapamycin on cell proliferation of U937. As
expected, HSC had inhibited cell proliferation. U937 cells, while inhibited
slightly, continued to proliferate without increasing in size. This deserves further
investigation.
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Our laboratory is particularly interested in exploiting inherent or
chemotherapeutically-induced differences in cell size between normal cells and
cancer cells as a possible approach to the physical destruction of enlarged cells.
Since Rapamycin and analogs of Rapamycin can control cell size by inhibiting
cell growth, they are antagonistic to cytoskeletal-directed anticancer
chemotherapeutic agents such as Vincristine, Taxol, and Cytochalasin B that can
cause cancer cells to become greatly enlarged.

Data already exists that suggests that Rapamycin can synergistically enhance or
inhibit chemotherapy.3,4 We would like to see whether Rapamycin concentration
will permit the leukemia cells to be trapped in an enlarged state by cytoskeletaldirected agents that trap dividing cells in mitosis or at cytokinesis while normal
cells remain out of the cell cycle and remain small. Moreover, cytoskeletaldirected agents prevent cells from proliferating. Since Rapamycin inhibited cell
proliferation slightly while inhibiting HSC proliferation completely, the drug-drug
interaction of Rapamycin and cytoskeletal-directed agents might be a potential
subject of interest. Further experiments should determine the interaction between
Rapamycin and its antagonist agents in both human leukemia cells and human
stem cells.
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Appendix A
Glossary
VEGF – vascular endothelial growth factor; plays a role in angiogenesis by
attracting and organizing vascular endothelial cells2,8,9.
HIF1-α – hypoxia-inducible factor 1α; A transcription factor involved in
angiogenesis, metabolism, proliferation, motility, adhesion, and survival2,9,10.
FKBP12 – FK506 binding protein; protein folding chaperone8,9,10.
FRB – FKBP12-Rapamycin binding domain5.
PIKK – phosphatidylinositol kinase-related kinase family, protein family that
phosphorylates other proteins to adjust their function8,9.
PI3K – phosphatidylinositol 3-kinase; oncoprotein that phosphorylates lipids,
resulting in their recruitment to the cell membrane.2,5,8,9
PI4K – phosphatidylinositol 4-kinase5.
FAT and FATC – a conserved kinase domain on the C-terminus of PIKK,
mediates protein-protein interaction and association11.
HEAT sequences – amino acid sequences (varying from 30 to 60 residues) that
appear in various proteins, including kinases; the motif consists of particular
arrangement of A and B helices; thought to play a role in protein/protein
interactions12.
PIP2 – phosphatidylinositol-4,5-phosphate5.
PIP3 – phosphatidylinositol-3,4,5-phosphate5.
PTEN – phosphatase and tensin homolog2.
9

PDK1 – 3-phosphoinositide-dependent protein kinase 1 .
Akt – enzymes that are members of the serine/threonine-specific protein kinase
family; involved in metabolism, proliferation and growth regulation2,9,10.
TSC1 – Tuberous sclerosis protein 1, hamartin protein, tumor suppressor2.
TSC2 – Tuberous sclerosis protein 2, tuberin, believed to be a tumor suppressor,
stimulates
GTP-ases2.

42

Rheb – Ras homolog enriched in brain, belongs to the Ras superfamily of GTPases, functions in cell proliferation2.
S6K1 – S6 kinase 1, phosphorylates ribosomal 6S protein9.
4E-BP1 – eukaryotic initiation factor 4E binding protein 1, initiate translation9.
hVPS34 – a class III PI3K required for activation of p70 S6 kinase5.
AICAR – 5-Aminoimidazole-4-carboxamide-1- -4-ribofuranoside (AICAR), an
analog of AMP, is widely used as an activator of AMP-kinase (AMPK), a protein
that regulates the responses of the cell to energy change13.
REDD1 and REDD2 – hypoxia-inducible genes, suppress mTORC15,14.
Pol – polymerase5.
TIF1A – tripartite motif-containing 24, also known as transcriptional intermediary
factor 1 alpha, involved in regulation of transcription8,10.
FHL1– four and a half LIM domains (Pol II associated transcription factor),
involved in many cellular processes8.
Rho1 – GTP-binding protein of the Rho subfamily of Ras-like proteins, involved
in establishment of cell polarity
PKC1 – protein kinase C1, pertains to a family of serine/threonine protein kinases
grouped by their activation mechanism8.
MAP(K) – mitogen-activated protein kinase; are serine-threonine kinases that
regulate a wide variety of cellular functions8.
ATG1 – Autophagy-specific gene 1; involved in autophagy8.

43

Capstone Summary
mTOR in Cell Signaling and Cell Size Enlargement as a Target for the ChemicoPhysical Therapy of Cancer
In 1970, Streptomyces hygroscopicus bacteria were discovered in the soil
samples from Easter Island.5 S. hygroscopicus was found to produce a strong
antifungal compound.1 This compound was named Rapamycin after the place of
its discovery.5 In the local language, Easter Island is called Rapa Nui.5
At a later date the cellular protein target of Rapamycin was identified in
mammalian cells.5 The protein was named “mTOR” for mammalian target of
Rapamycin.1,5 mTOR is a kinase protein, meaning it adds a phosphate group to
other proteins in order to adjust their function.5 About 40%–60% of mTOR’s
primary amino acid sequence is identical to a larger family of kinases, the
phosphatidylinositol kinase-related kinase (PIKK) family.5
mTOR is a large protein; it is about 280 kDa.5 It is located in the
cytoplasm at a convergent point of many signaling pathways, which allows
mTOR to integrate the incoming signals and determine the appropriate response
to these signals.1,5
mTOR is highly conserved across eukaryotic species.5 In the cytosol,
mTOR exists in two distinct complexes.1,5,7 mTOR complex 1 binds specific
proteins that are different from the proteins mTOR complex 2 binds.1,5 mTOR
complex 1 is responsible for determining cell’s metabolism, growth, and
proliferation (cell division).1,5 It is sensitive to Rapamycin.1,5 Recently it was
discovered that mTOR complex 2 is responsible for actin reorganization.1,5,7 Actin
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is protein responsible for cell movement, shape and location. This complex is
Rapamycin insensitive.1,5,7
Cells receive various signals such as growth factors (tell the cell when to
grow), energy levels (AMP/ATP ratio), nutrient presence (presence of amino
acids), and stress the cell experiences (for example, low oxygen levels).1,5 mTOR
integrates these signals and determines the appropriate response. mTOR regulates
ribosome biogenesis (whether or not to form ribosomes), transcription/translation
(what genes to activate and what genes to deactivate), actin assembly (to move or
not to move), macroautophagy (in time of starvation to begin degrading
components of self).1,5
mTOR has been linked with many cancers such as melanoma, lymphoma,
breast cancer and others.2 mTOR itself is not mutated in cancers usually.2 It is all
the incorrect signaling the cancer cell experiences that allows mTOR to determine
an inappropriate response.2 Cells with mTOR inappropriately activated can
proceed with cell enlargement and cell proliferation in the absence of normal cell
signaling.2 Rapamycin inhibits mTOR, making it unable to perform its function.1,5
For this reason, Rapamycin has been used in cancer therapy. For a cancer cell
this means being unable to grow large and to divide.
In our laboratory we attempt to make cells larger either by synchronizing
cell divisions to occur at the same time or by using therapeutic agents such as
cytoskeleton-directed agents. Rapamycin is an agent that does the opposite, it
makes cells smaller. We wanted to determine the effect of Rapamycin on human
stem cells (normal cells) and human leukemia cells (cancer cells). Particularly, we
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wanted to determine the concentration of Rapamycin that affects human stem
cells (HSC) much more strongly than human leukemia cells (U937 cells).
Ultimately we wanted to know if there is a concentration of Rapamycin that
inhibits the cell size and cell proliferation of HSC but does not inhibit cell size
and cell proliferation of U937 leukemia cells.
We performed experiments where we treated both HSC and U937
leukemia cells with various Rapamycin concentrations and observed the effects of
Rapamycin on cell enlargement and cell proliferation. In experiment 1 we treated
both HSC and U937 cells with Rapamycin concentrations of 800, 400, 200, 100,
50, and 25 nM. Both cell types showed cell size inhibition, meaning cells became
smaller. At these concentrations there appeared to be no difference in the way
Rapamycin affected HSC and U937 cells. HSC had cell size inhibited by 20% to
30%. U937 cells had cell size inhibited by 12% to 30%. However, the effect was
not uniform for both cell types. For example, HSC cells were inhibited the most
by 50 nM Rapamycin concentration while U937 cells were inhibited the most by
800 nM concentration.
Both cell types showed cell proliferation inhibition as well. Both cell types
should have been proliferating very little in the presence of Rapamycin. Indeed,
HSC proliferated much less than the U937 cells did. However, U937 cells
proliferated a lot more than we expected. For U937 cells proliferation was not
dose dependent either, meaning, cells treated with 50 and 200 nM proliferated
more than had cells treated with 100 and 800 nM Rapamycin.
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In experiment 2 we treated only the U937 leukemia cells. In the previous
experiment we saw that 800 to 25 nM Rapamycin had inhibitory effect on the
U937 cells. In this experiment we treated U937 cells with lower Rapamycin
concentrations 40, 20, 10, 5, 2 and 1nM because we wanted to determine the
concentration of Rapamycin that would have no effect on cell size. We found that
concentrations as low as 1 and 2 nM had an inhibitory effect on cell size of the
U937 cells.
Moreover, low concentrations of Rapamycin inhibited cell proliferation
slightly. However, cells continued to proliferate despite the presence of
Rapamycin. In experiment 2 we also removed Rapamycin a few days after
treatment to see whether Rapamycin had any toxicity on cells growth. We found
that there was no toxicity due to Rapamycin.
In experiment 3 we treated both HSC and U937 cells with Rapamycin
concentrations 32, 16, 8, 4, 2, 1, and 0.5 nM and compared the effect of
Rapamycin on cell size and cell proliferation of both cell types. In terms of cell
size, we did not find much difference in the way HSC and U937 responded to
Rapamycin. We found that even low Rapamycin concentrations had an effect on
cell size even of both HSC and U937 cells. However, in terms of cell proliferation
there was a distinct difference in how the cells responded to Rapamycin. HSC
cells proliferated very little or not at all in the presence of Rapamycin. When
compared to non treated cells, at 2 nM Rapamycin HSC cells increased by 2-fold
while U937 cells increased by 8-fold. This difference in cell number increase is
startling.
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In summary, in terms of cell size we did not find a distinct difference
between HSC and U937 cells. However, we found a startling difference in the
way the cells responded to Rapamycin in terms of cell proliferation. Since
Rapamycin and analogs of Rapamycin can control cell size by inhibiting cell
growth, they are antagonistic to cytoskeletal-directed anticancer chemotherapeutic
agents such as Vincristine, Taxol, and Cytochalasin B that can cause cancer cells
to become greatly enlarged. In our laboratory we want to exploit inherent or
chemotherapeutically-induced differences in cell size between normal cells and
cancer cells in order to use outside physical force to preferentially destroy
enlarged cells. In the future we would like to determine the effect of combination
therapy of Rapamycin and cytoskeletal-directed agents. It is possible that HSC
cells treated with Rapamycin and Vincristine, for example, will remain small
while U937 cells will become preferentially big. These enlarged U937 cells would
be subject to physical destruction while normal cells (HSC) are protected from the
physical destruction by remaining small in size.

